NWQ Investment Management Company LLC lowered its stake in shares of Sanofi SA (NYSE:SNY) by 2.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 369,252 shares of the company’s stock after selling 10,421 shares during the quarter. NWQ Investment Management Company LLC’s holdings in Sanofi were worth $15,878,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds also recently added to or reduced their stakes in SNY. State Street Corp raised its holdings in Sanofi by 401.3% during the second quarter. State Street Corp now owns 41,183 shares of the company’s stock worth $1,972,000 after purchasing an additional 32,967 shares in the last quarter. BNP Paribas Arbitrage SA raised its holdings in Sanofi by 8.3% during the third quarter. BNP Paribas Arbitrage SA now owns 15,374 shares of the company’s stock worth $765,000 after purchasing an additional 1,183 shares in the last quarter. Toronto Dominion Bank raised its holdings in Sanofi by 36.7% during the third quarter. Toronto Dominion Bank now owns 5,540 shares of the company’s stock worth $277,000 after purchasing an additional 1,486 shares in the last quarter. Cambridge Investment Research Advisors Inc. raised its holdings in Sanofi by 7.7% during the third quarter. Cambridge Investment Research Advisors Inc. now owns 27,014 shares of the company’s stock worth $1,345,000 after purchasing an additional 1,941 shares in the last quarter. Finally, SG Americas Securities LLC raised its holdings in Sanofi by 66.3% during the third quarter. SG Americas Securities LLC now owns 85,591 shares of the company’s stock worth $4,262,000 after purchasing an additional 34,112 shares in the last quarter. 8.94% of the stock is currently owned by institutional investors.
Sanofi SA (NYSE SNY) opened at $40.40 on Wednesday. The company has a current ratio of 1.70, a quick ratio of 1.26 and a debt-to-equity ratio of 0.25. The stock has a market cap of $102,499.30, a P/E ratio of 11.07, a PEG ratio of 2.16 and a beta of 0.92. Sanofi SA has a 1 year low of $38.14 and a 1 year high of $50.65.
The firm also recently announced an annual dividend, which will be paid on Monday, June 4th. Stockholders of record on Thursday, May 10th will be given a dividend of $1.8609 per share. The ex-dividend date of this dividend is Wednesday, May 9th. This is a positive change from Sanofi’s previous annual dividend of $1.58. This represents a dividend yield of 4.72%. Sanofi’s dividend payout ratio (DPR) is 30.14%.
A number of analysts have weighed in on the stock. Sanford C. Bernstein reissued a “market perform” rating and set a $45.00 price objective (down previously from $50.00) on shares of Sanofi in a report on Thursday, February 8th. ValuEngine cut shares of Sanofi from a “buy” rating to a “hold” rating in a report on Friday, February 2nd. Zacks Investment Research cut shares of Sanofi from a “hold” rating to a “sell” rating in a report on Wednesday, February 14th. Bank of America cut shares of Sanofi from a “buy” rating to a “neutral” rating in a report on Wednesday, December 6th. Finally, TheStreet cut shares of Sanofi from a “b-” rating to a “c+” rating in a report on Tuesday, February 13th. Three research analysts have rated the stock with a sell rating, ten have given a hold rating and two have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $49.33.
Sanofi Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.